Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Ca
View Patent ↗The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
1. A method for treating overactive bladder, which comprises orally administering to an individual in need thereof a therapeutically effective amount of an active agent wherein said agent is Ziconotide (ω-conotoxin MVIIA) or a pharmaceutically acceptable salt, ester, amide, prodrug, active metabolite or derivative thereof.
2. The method of claim 1 , wherein the active agent is contained within a pharmaceutical formulation.
3. The method of claim 2 , wherein the pharmaceutical formulation is a unit dosage formulation.
4. The method of claim 1 , wherein the active agent is administered on an as-needed basis.
5. The method of claim 1 , wherein the active agent is administered prior to commencement of an activity wherein suppression of the symptoms of a overactive bladder would be desirable.
6. The method of claim 5 , wherein the active agent is administered from about 0 to about 3 hours prior to commencement of an activity wherein suppression of said symptoms would be desirable.
7. The method of claim 2 , wherein the formulation is a controlled release dosage formulation.
8. The method of claim 7 , wherein the formulation is a delayed release dosage formulation.
9. The method of claim 7 , wherein the formulation is a sustained release dosage formulation.
10. The method of claim 9 , wherein the sustained release dosage formulation provides drug release over a time period of from about 6 hours to about 8 hours.
11. The method of claim 1 , wherein said overactive bladder is OAB Wet.
12. The method of claim 1 , wherein said overactive bladder is OAB Dry.
13. The method of claim 2 , wherein the pharmaceutical formulation further comprises an additional active agent.
14. The method of claim 13 , wherein the additional active agent is ω-conotoxin GVIA or a salt, enantiomer, analog, ester, amide, prodrug, active metabolite, or derivative thereof.